COLON AND RECTAL CANCER DRUGS MARKET ANALYSIS
Colon and Rectal Cancer Drugs Market – Restraints
Lack of development in the neoadjuvant/adjuvant pipeline agents for the treatment of high risk colorectal cancer resulted in slower growth of colon and rectal cancer drugs market. For instance, according to the data published in the National Center for Biotechnology Information (NCBI) in April 2016, there is lack of clinical trials of systemic adjuvant, neoadjuvant, and perioperative chemotherapy for the treatment of colorectal liver metastases (CRLM). These offers lucrative opportunity for the key players to develop new treatment therapy using neoadjuvant agents for resected patients.
Furthermore, improper reimbursement policies for colorectal cancer treatment in certain countries hampers growth of the global colon and rectal cancer drugs market. For instance, according to the comparison study published in the American Society of Clinical Oncology (ASCO) 2018 meeting, treatment cost of metastatic colorectal cancer in Western Washington (U.S.) is higher than the province of British Columbia (BC) in Canada, with no significant difference in the outcome.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
